Tahmineh Yazdi

Medicine · Health Sciences

4h-index55citations10works1.52yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hepatitis C virus research(9), Hepatitis B Virus Studies(9), Hepatitis Viruses Studies and Epidemiology(4), HIV/AIDS drug development and treatment(3), Liver Disease Diagnosis and Treatment(2)

Publications10 total

Eight-year Results from Two Randomized Phase 3 Trials of Tenofovir Alafenamide for Chronic Hepatitis B Virus Infection in China
Journal of Clinical and Translational Hepatology·2026Open Access
IDDF2024-ABS-0208 No resistance to tenofovir alafenamide (TAF) in adult, HBeAg-positive and HBeAg-negative participants with chronic hepatitis B infection treated with TAF for up to 8 years
2024
SAT-371 No amino acid substitution in HBV PreS1, HDAg, or NTCP associated with suboptimal response to bulevirtide in combination with pegylated interferon alfa-2a treatment in participants with chronic hepatitis delta: results from MYR204 a phase 2b study
Journal of Hepatology·2024
Five-year Treatment with Tenofovir Alafenamide Achieves High Rates of Viral Suppression, Alanine Aminotransferase Normalization, and Favorable Bone and Renal Safety in Chinese Chronic Hepatitis B Patients
Journal of Clinical and Translational Hepatology·2024· 6 citedOpen Access
Broad-spectrum activity of bulevirtide against clinical isolates of HDV and recombinant pan-genotypic combinations of HBV/HDV
JHEP Reports·2023· 8 citedOpen Access
No virologic resistance to bulevirtide monotherapy detected in patients through 24 weeks treatment in phase II and III clinical trials for chronic hepatitis delta
Journal of Hepatology·2023· 22 cited
Polymorphic analysis of bulevirtide sequence in PreS1 of large HBsAg across HBV genotypes A-H
Journal of Hepatology·2022
Bulevirtide is broadly active against all HDV genotypes expressing envelopes from HBV genotypes A-H and a large panel of clinical isolates
Journal of Hepatology·2022· 3 cited
No detectable resistance to bulevirtide in participants with chronic hepatitis D (CHD) through 24 weeks of treatment
Journal of Hepatology·2022· 1 cited
Advantages and Limitations of Androgen Receptor-Based Methods for Detecting Anabolic Androgenic Steroid Abuse as Performance Enhancing Drugs
PLoS ONE·2016· 15 citedOpen Access

Frequent Co-authors

Roberto Mateo(8), Simin Xu(7), Savrina Manhas(7), Lindsey May(7), Hongmei Mo(7), Thomas Aeschbacher(6), Yang Liu(5), Ross Martin(5), Dong Han(5), Silvia D. Chang(5), Julius Hollnberger(4), Bin Han(4), John F. Flaherty(4), Christopher J. Richards(4), Stephan Urban(4), Vithika Suri(3), Tarik Asselah(3), Evguenia Maiorova(3), Caleb Marceau(3), Evguenia S. Svarovskaia(3)